Journal of Environmental and Public Health

Journal of Environmental and Public Health / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 401340 |

Oluranti J. Obisesan, Olugbenga A. Olowe, Samuel S. Taiwo, "Phenotypic Detection of Genitourinary Candidiasis among Sexually Transmitted Disease Clinic Attendees in Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria", Journal of Environmental and Public Health, vol. 2015, Article ID 401340, 7 pages, 2015.

Phenotypic Detection of Genitourinary Candidiasis among Sexually Transmitted Disease Clinic Attendees in Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria

Academic Editor: Ike S. Okosun
Received10 Feb 2015
Revised17 Apr 2015
Accepted20 Apr 2015
Published06 May 2015


The management of genitourinary candidiasis (GC) is fraught with challenges, especially, in an era of increasing antifungal resistance. This descriptive cross-sectional study conducted between May 2013 and January 2014 determined the prevalence and characteristics of GC and the species of Candida among 369 attendees of a Sexually Transmitted Disease (STD) clinic of Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria. Appropriate urogenital specimen collected from each attendee was examined by microscopy and culture for Candida, with preliminary species identification by CHROMAgar Candida and confirmation by Analytical Profile Index (API) 20C AUX. The age range of attendees was 1-80 years, mean age was years, and male to female ratio was 1 to 3. The prevalence of genitourinary candidiasis was 47.4%, with 4.9% in males and 42.5% in females (). The age groups 31–45 and 16–30 have the highest prevalence of 23.3% and 16.8%, respectively. The species of Candida recovered include Candida glabrata 46.9%, Candida albicans 33.7%, Candida dubliniensis 9.7%, Candida tropicalis 5.7%, Candida krusei 1.7%, Candida lusitaniae 1.7%, and Candida utilis 0.6%. This study reported non-C. albicans Candida, especially C. glabrata, as the most frequently isolated species in GC, contrary to previous studies in this environment and elsewhere.

1. Introduction

Genitourinary candidiasis is a fungal infection of the genital and urinary tracts caused by Candida, presenting as vulvovaginal candidiasis in women, balanitis and balanoprostitis in men, and candiduria in both sexes [1, 2]. Candida species are normal microbiota of the respiratory tract, gastrointestinal tract, mouth, and vagina, and cause opportunistic infections when altered host conditions enable the fungus to proliferate. Although genitourinary candidiasis can occur in both immunocompetent and immunocompromised persons, it is a cause of morbidity and mortality in immunocompromised patients in particular [3]. Risk factors associated with genitourinary candidiasis include sexual contacts, poor genital hygiene, urinary instrumentation, urinary obstruction, and incomplete bladder emptying [46]. Among Candida species implicated, epidemiological studies have shown that C. albicans is the most commonly isolated species [69]. The newly emerging non-Candida albicans Candida, including Candida glabrata, Candida krusei, Candida tropicalis, Candida lusitaniae, and Candida parapsilosis, are however now implicated as causative agents [1014] of genitourinary candidiasis.

The incidence of genitourinary candidiasis varies in relation to gender, host susceptibility, and hospital settings. The incidence is higher in women and among hospitalized patients [79], particularly in intensive care [7] and burn units [15]. The incidence is also high in pregnant women and in HIV-infected patients [16, 17], in patients with uncontrolled diabetes mellitus [1821], and in individuals with multiple sexual partners [5, 16, 22].

Genitourinary candidiasis can be symptomatic or asymptomatic [23, 24]. Vulva pruritus and vaginal discharge are the most frequent symptoms of vulvovaginal candidiasis [25]. The discharge, which is usually adherent but not offensive, is typically cottage cheese-like in appearance but may range from watery to homogenously thick discharge. Other symptoms include vaginal soreness from scratching, vulva burning, dyspareunia, and dysuria. There may be erythema and swelling of the labia and vulva on examination but the cervix usually appears normal [25, 26]. Asymptomatic candiduria often occurs in hospitalized patients with indwelling catheters, and these patients usually show none of the signs or symptoms associated with urinary tract infection [3]. Although candiduria frequently occurs, especially in catheterized patients, symptomatic candida cystitis is rare, as bladder is relatively resistant to Candida invasion. When it occurs, however, it may present with signs and symptoms of bladder irritation including dysuria, hematuria, frequency, urgency, and suprapubic tenderness [27]. Conversely, symptomatic candida cystitis is rare in noncatheterized patients; however prostatic abscess caused by Candida species is not uncommon in male patients with diabetes mellitus [15, 28].

In our clinic, the diagnosis of genitourinary candidiasis is often made on clinical ground and by conventional laboratory detection of Candida with wet film/Gram smear microscopy, and culture on Sabouraud Dextrose Agar followed by identification based on colonial morphology, germ tube test, and formation of chlamydospores on cornmeal agar [27]. However other non-C. albicans species such as C. glabrata and C. dubliniensis are known to exhibit morphologic and biochemical characteristics indistinguishable from C. albicans. This conventional method therefore may not differentiate the Candida species, and this gives tendency to overreporting of C. albicans as the most frequent cause of genitourinary candidiasis.

In view of the changing epidemiology of fungi infections occasioned by worldwide increased incidence of immunocompromising diseases coupled with increased use of immunosuppressive therapies and resistance to traditional antifungi agents [29], it is imperative to employ methods that will identify species of Candida that may exhibit different susceptibility to currently available antifungi agents. These methods include the use of selective chromogenic media such as CHROMAgar which allow rapid identification of different Candida species based on colour changes produced from utilization of chromogenic substrates, facilitating detection of even mixed infections with more than one Candida species [29]. Commercial identification kits such as the Analytical Profile Index (API) that measures metabolic activities of Candida, ELISA antigen detection, and molecular methods such as the Polymerase Chain Reaction (PCR) tests can reliably differentiate C. albicans from non-C. albicans Candida species [11, 13]. However, only few laboratories in our environment have financial capability to employ these methods for routine identification of Candida isolates.

In this study, we employed conventional culture for initial isolation of Candida and identify the species of Candida using CHROMAgar Candida and then confirmed the species by the API 20C AUX. The objectives are to determine the prevalence and characteristics of genitourinary candidiasis as well as the species of Candida among attendees of our Sexually Transmitted Disease (STD) clinic. This information is necessary for proper management of genitourinary candidiasis in view of recent reports in our hospital of apparent failed treatment among women treated for vaginal candidiasis with azole antifungi agents.

2. Materials and Methods

2.1. Study Design and Setting

A descriptive cross-sectional study was conducted during the period May 2013 and January 2014 at Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria. The research project proposal was approved by the Ethical Committee of the institution. Informed consent was obtained from each attendee prior to the start of the study.

2.2. Subjects

All consenting attendees (all age groups and gender) of the Sexually Transmitted Disease (STD) clinic for purposes of evaluation on account of STDs or genitourinary complaints were recruited into the study. No attendee was excluded except those who did not give informed consent. Sociodemographic and clinical data of each attendee were collected into an interview protocol form. Our STD clinic has recently been renamed Genitourinary Medicine (GUM) clinic to accommodate all cases of genitourinary complaints aside STDs.

2.3. Specimen Collection

Appropriate specimen types were collected in relation to gender, age, and complaints. Vulvovaginal and urethra swabs were collected by qualified medical personnel using cotton tipped swab. High vaginal and endocervical swabs were collected after speculum examination from posterior fornix and endocervix, respectively. All swabs were immediately transported to the Medical Microbiology Laboratory of the hospital for processing. For urine specimen, each adult attendee was instructed (verbal and written) to collect 10 mL of a clean-catch midstream urine specimen into a sterile screw-capped wide-mouth container and immediately deliver it to the laboratory. For children, parents or guardians were instructed appropriately how to collect urine specimen from the child into sterile bottle.

2.4. Wet Film Microscopy

A swab stick containing specimen was emulsified with small volume of normal saline (0.9% NaCl) on a clean grease-free glass slide and covered with a cover slip. The preparation was examined under the microscope using 10x and 40x objective lenses for oval budding yeast presumed to be Candida [27].

A deposit of centrifuged urine was placed on a glass slide, covered with a cover slip, and examined microscopically at 400x magnifications for presence of yeast cells and other cells such as trichomonads and clue cells.

2.5. Gram Stain Microscopy

Smears of swabs were made from the saline mixture and urine deposit on a clean glass slide. Each smear was air-dried and heat-fixed by passing over a Bunsen burner flame three times to fix the slide. The slide was Gram-stained using recommended procedure and then examined for oval yeast cells [27, 30].

2.6. Qualitative Culture and Identification of Candida Species

Swabs and urine specimens were inoculated onto Sabouraud Dextrose Agar (Oxoid, UK) supplemented with chloramphenicol and incubated at 37°C for 48 hours for qualitative culture analysis. Colonies from SDA were first Gram-stained and those that showed Gram positive yeast were then subcultured on CHROMAgar Candida (Paris, France) selective and differential medium. With the inclusion of chromogenic substrates in the medium, the colonies of C. albicans, C. tropicalis, C. glabrata, and C. krusei produce different colors, thus allowing the detection of these Candida species. Colonies of C. albicans appeared as light to medium green, C. tropicalis colonies as dark blue to metallic blue, C. dubliniensis as dark green, C. krusei colonies as pale pink with white edge rough, C. glabrata as pink to violet surface with pale edges, C. lusitaniae as pink to lavender, and C. utilis as glossy pink. All Candida species identified on CHROMAgar were further subjected to sugar assimilation and fermentation tests using API Candida (API BioMérieux, France) to confirm each species. Fungi susceptibility testing could not be done due to lack of facility in our laboratory at the time of this study.

2.7. Data Entry and Statistical Analysis

Sociodemographic, clinical, and microbiological data were entered into SPSS (Statistical Package for the Social Sciences) version 16.0 on a Window 7 laptop computer for analysis. The Chi-square or Fisher exact test was used to estimate significant differences between categorical variables. Values were considered to be statistically significant when the value obtained was less than 0.05.

3. Results

3.1. Study Population

A total number of 369 attendees (mean age: years, age range: 1 to 80 years) were studied of which 91 (24.7%) were males and 278 (75.3%) were females, giving a M : F ratio of 1 : 3. The age group distribution and sociodemographic characteristics of the study population are shown in Table 1. The age groups 31–45 and 16–30 constitute the largest group patronizing the STD clinic with 53.9% (199 of 369) and 28.2% (104 of 369), respectively. Of the 369 attendees, 86 (23.3%) were pregnant women, 94 (25.5%) had underlying HIV infection, 70 (18.9%) had diabetes mellitus (DM), 33 (8.9%) had underlying urinary tract infection (UTI), and 86 (23.3%) were visiting the clinic for fear of having contacted STDs (venereophobia) but had no underlying medical condition or illness.

CharacteristicsNumber of attendees%

(1) Age group (years)MaleFemaleTotal
(2) Marital status
 Married but separated5815.7
 Married but divorced/widowed7520.3
(3) Educational status
 Artisan/skilled workers/uneducated9224.9
(4) Occupational status
 Full-time employment16243.9
 Part-time employment11430.9
 Not employed9325.2
(5) Categories of attendees
 Pregnant women8623.3
 DM 7018.9
 Apparently healthy8623.3

3.2. Prevalence and Characteristics of Genitourinary Candidiasis

Table 2 shows the prevalence of genitourinary candidiasis in the study population. Of the 369 attendees, 175 were positive for Candida, giving a prevalence of genitourinary candidiasis of 47.4% (175 of 369) in the study, with 4.9% (18 of 369) in males and 42.5% (157 of 369) in females (OR 1.9, ). The age groups 31–45 and 16–30 which constitute the largest groups patronizing the clinic also have the highest prevalence of genitourinary candidiasis with 23.3% and 16.8%, respectively (). Symptoms of genitourinary candidiasis were seen in only 72 (41.1%) of the 175 attendees positive for Candida which include 39 pregnant women, 1 HIV-infected individual, 25 DM patients, 7 UTI patients, and none of the apparently healthy attendees. One hundred and three (58.9%) of those positive for Candida were asymptomatic and include 12 pregnant women, 39 HIV-infected individuals, 9 DM patients, 3 UTI patients, and 40 apparently healthy individuals (Table 3 and Figure 1).

Age group (years)Gender Total Prevalence rate (%)95% CIORp value



CategoriesNumber of attendeesNumber of those positive for Candida Number of symptomatic attendeesNumber of asymptomatic attendees

Apparently healthy8640040


3.3. Frequency of Isolation of Candida Species

Table 4 shows the species of Candida recovered in the study and their frequency of isolation. They include Candida glabrata 82 (46.9%), Candida albicans 59 (33.7%), Candida dubliniensis 17 (9.7%), Candida tropicalis 10 (5.7%), Candida krusei 3 (1.7%), Candida lusitaniae 3 (1.7%), and Candida utilis 1 (0.6%). Both C. albicans and non-C. albicans Candida species were recovered across all categories of attendees without any particular pattern or preference ( > 0.05, Table 5). The recovery rate of Candida species from clinical specimens was highest with urine samples followed by vulvovaginal swabs and least from urethral swab (Table 6).

Candida speciesFrequencyPercentage (%)

Candida glabrata 8246.9
Candida albicans 5933.7
Candida dubliniensis 179.7
Candida tropicalis 105.7
Candida krusei 31.7
Candida lusitaniae 31.7
Candida utilis 10.6


Categories of attendeesC. albicans (%)Non-C. albicans Candida (%)Total (%) value

Apparently healthy162440

Total59 (33.7)116 (66.3)175 (100)

Clinical specimensNumber of samplesNumber of those positive for Candida % Recovery rate value

Vulvovaginal swab26612446.627.678
Urethral swab2514.0


4. Discussion

The incidence of genitourinary candidiasis has dramatically increased in recent years as a result of increase in the incidence of immunodeficiency diseases such as HIV/AIDS, malignancies, metabolic dysfunctions, and the increasing use of immunosuppressive therapies for organ transplantation as well as the use of broad spectrum antibiotic therapy [29]. This study determined the prevalence and characteristics of genitourinary candidiasis as well as the species of Candida among attendees of Sexually Transmitted Disease (STD) clinic of Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria. The prevalence of 47.4% reported in our study agrees with rates reported in previous studies of Enweani et al. [31], Sehgal [32], and Okungbowa et al. [33] conducted on similar populations and who recorded 40.7%, 54%, and 57.3% rates, respectively. However, the rate in our study was far less than the rate reported in a more recent study by Farooqi et al. [34]. The differences in rates reported may be attributed to the geographical variability, period of specimen collection, methods of identification, and differences in study population.

Candida glabrata, a non-C. albicans Candida, was the most prevalent causative agent of genitourinary candidiasis in this study with 46.9%. This is in conformity with Okungbowa et al. [33] who reported C. glabrata as the most prevalent Candida species in their study with 33.7% and Srujana et al. [35] with 50.4%. Other studies that have reported non-C. albicans as predominant isolates such as Malini [36] with 54.1% and Ragini et al. [37] with 69.7% also agree with the 66.3% of non-C. albicans Candida isolates reported in our current study. However some recent studies [6, 38] still reported C. albicans as the predominant Candida species isolated in genitourinary candidiasis. The significance of our finding is in the light of postulates by some investigators that C. glabrata may have emerged as breakthrough vaginal infections in women receiving long-term maintenance low-dose fluconazole prophylaxis [24]. There is a high possibility in our environment that C. glabrata and other non-C. albicans may have been responsible for recurrent vaginal candidiasis and apparent failed treatment seen in many women treated with ketoconazole and fluconazole, two most important antifungi azoles routinely used in our hospital for treating candidiasis (personal communication). We also noted higher Candida recovery from urine specimen, especially for the non-C. albicans Candida, than from vulvovaginal or urethral swabs. Examination of urine may therefore serve as credible alternative, especially when vulvovaginal swab cultures are persistently negative, but the patients continue to experience symptoms of genitourinary candidiasis.

In this study, genitourinary candidiasis occurred most frequently in the age groups 31–45 and 16–30 years which together had prevalence rate of 40.1%. This age bracket, which encompasses teenagers, adolescents, and young adults, represents the most sexually active population group, with predisposition to increased sexual activities, an important risk factor for genitourinary candidiasis [5, 16, 22, 39]. This observation has been similarly reported by other researchers in Nigeria [33, 38, 40] and elsewhere [32]. It is however interesting to note that we isolated Candida from urine of 7 out of the 10 children (age group 1–15 years) enrolled in the study, 6 of whom were prepubertal girls and 1 was a male child. All 7 had symptoms of urinary tract infection and non-C. albicans were recovered from 5 of them. Candida is a normal flora of the vagina of prepubertal girls and usually kept at bay by the lactobacillus flora. However, a distortion in the normal lactobacilli balance, especially following broad spectrum antibiotic therapy, sexual activity, or use of contraceptives, may enable Candida, especially C. glabrata, to proliferate to produce symptomatic genitourinary disease [4143]. We could not ascertain the factors that predisposed these children to candidiasis. However, three of them had received antibiotic therapy two weeks before the study. The preponderance of females attending our STD clinic and the high prevalence of genitourinary candidiasis in them have previously been established in our institution [44].

Genitourinary candidiasis can be symptomatic or asymptomatic [23, 24]. In our study, only 41.1% of the clinic attendees were symptomatic of candidiasis, most of whom were pregnant women and diabetic patients, in agreement with what has been previously reported [19, 45]. The apparently healthy attendees (who were probably venereophobic) and the HIV-infected patients were largely asymptomatic, although Candida was isolated from their urine or vulvovaginal swabs. One limitation in our study was that we did not perform quantitative Candida culture to determine whether density of organisms correlated with symptomatology; hence we are unable to provide explanation why these groups of attendees were asymptomatic. However, it is generally established that high inoculum of fungi organisms correlate with fungi pathogenicity and symptomatology [3, 46]. Asymptomatic genitourinary candidiasis usually does not require specific treatment as correcting any risk factor can result in remission of disease. However, immunocompromised patients, who are asymptomatic carrier of Candida, are at risk of developing invasive fungal infections; hence all HIV-infected and diabetes mellitus patients in our study and all symptomatic patients were offered appropriate antifungi therapy.

5. Conclusion

The findings in this study showed that C. albicans, usually reported to be the most frequently isolated species in genitourinary candidiasis, was not the main species recovered. The non-C. albicans Candida, especially C. glabrata, were most frequently isolated. Phenotypic methods of identification used in this study proved adequate for the primary isolation, presumptive identification, and speciation of Candida.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


  1. S. Edwards, “Balanitis and balanoposthitis: a review,” Genitourinary Medicine, vol. 72, no. 3, pp. 155–159, 1996. View at: Google Scholar
  2. C. Lisboa, A. Ferreira, C. Resende, and A. G. Rodrigues, “Infectious balanoposthitis: management, clinical and laboratory features,” International Journal of Dermatology, vol. 48, no. 2, pp. 121–124, 2009. View at: Publisher Site | Google Scholar
  3. J. M. Achkar and B. C. Fries, “Candida infections of the genitourinary tract,” Clinical Microbiology Reviews, vol. 23, no. 2, pp. 253–273, 2010. View at: Publisher Site | Google Scholar
  4. L. O. Eckert, S. E. Hawes, C. E. Stevens, L. A. Koutsky, D. A. Eschenbach, and K. K. Holmes, “Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm,” Obstetrics & Gynecology, vol. 92, no. 5, pp. 757–765, 1998. View at: Publisher Site | Google Scholar
  5. M. G. Marin, R. King, S. Sfameni, and G. J. Dennerstein, “Adverse behavioral and sexual factors in chronic vulvar disease,” The American Journal of Obstetrics and Gynecology, vol. 183, no. 1, pp. 34–38, 2000. View at: Publisher Site | Google Scholar
  6. E. E. Akortha, V. O. Nwaugo, and N. O. Chikwe, “Antifungal resistance among Candida species from patients with genitourinary tract infection isolated in Benin City, Edo state, Nigeria,” African Journal of Microbiology Research, vol. 3, no. 11, pp. 694–699, 2009. View at: Google Scholar
  7. D. R. Schaberg, D. H. Culver, and R. P. Gaynes, “Major trends in the microbial etiology of nosocomial infection,” The American Journal of Medicine, vol. 91, no. 3, pp. 72S–75S, 1991. View at: Google Scholar
  8. C. A. Kauffman, J. A. Vazquez, J. D. Sobel et al., “Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group,” Clinical Infectious Diseases, vol. 30, no. 1, pp. 14–18, 2000. View at: Publisher Site | Google Scholar
  9. F. Álvarez-Lerma, J. Nolla-Salas, C. León et al., “Candiduria in critically ill patients admitted to intensive care medical units,” Intensive Care Medicine, vol. 29, no. 7, pp. 1069–1076, 2003. View at: Publisher Site | Google Scholar
  10. K. C. Hazen, “New and emerging yeast pathogens,” Clinical Microbiology Reviews, vol. 8, no. 4, pp. 462–478, 1995. View at: Google Scholar
  11. J. Xu, C. M. Boyd, E. Livingston, W. Meyer, J. F. Madden, and T. G. Mitchell, “Species and genotypic diversities and similarities of pathogenic yeasts colonizing women,” Journal of Clinical Microbiology, vol. 37, no. 12, pp. 3835–3843, 1999. View at: Google Scholar
  12. K. H. Abu-Elteen, “Increased incidence of vulvovaginal candidiasis caused by Candida glabrata in Jordan,” Japanese Journal of Infectious Diseases, vol. 54, no. 3, pp. 103–107, 2001. View at: Google Scholar
  13. P. P. Chong, Y. L. Lee, B. C. Tan, and K. P. Ng, “Genetic relatedness of Candida strains isolated from women with vaginal candidiasis in Malaysia,” Journal of Medical Microbiology, vol. 52, no. 8, pp. 657–666, 2003. View at: Publisher Site | Google Scholar
  14. L. A. Namkinga, M. I. N. Matee, A. K. Kivaisi, and C. Moshiro, “Prevalence and risk factors for vaginal candidiasis among women seeking primary care for genital infections in Dar Es Salaam, Tanzania,” East African Medical Journal, vol. 82, no. 3, pp. 138–143, 2005. View at: Google Scholar
  15. M.-E. Bougnoux, G. Kac, P. Aegerter et al., “Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome,” Intensive Care Medicine, vol. 34, no. 2, pp. 292–299, 2008. View at: Publisher Site | Google Scholar
  16. A. Spinillo, G. Pizzoli, L. Colonna, S. Nicola, F. de Seta, and S. Quaschino, “Epidemiology characteristics of women with idiopathic recurrent vulvo vaginal candidiasis (VVC),” Obstetrics & Gynecology, vol. 81, pp. 721–727, 1993. View at: Google Scholar
  17. P. L. Fidel Jr., J. A. Vazquez, and J. D. Sobel, “Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans,” Clinical Microbiology Reviews, vol. 12, no. 1, pp. 80–96, 1999. View at: Google Scholar
  18. J. D. Sobel, “Pathogenesis and treatment of recurrent vulvovaginal candidiasis,” Clinical Infectious Diseases, vol. 14, no. 1, pp. S148–S153, 1992. View at: Publisher Site | Google Scholar
  19. R. Goswami, V. Dadhwal, S. Tejaswi et al., “Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status,” Journal of Infection, vol. 41, no. 2, pp. 162–166, 2000. View at: Publisher Site | Google Scholar
  20. E. M. de Leon, S. J. Jacober, J. D. Sobel, and B. Foxman, “Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes,” BMC Infectious Diseases, vol. 2, article 1, 2002. View at: Publisher Site | Google Scholar
  21. R. Faraji, M. A. Rahimi, F. Rezanmadani, and M. Hashemi, “Prevalence of vaginal candidiasis infection in diabetic women,” African Journal of Microbiology Research, vol. 6, no. 11, pp. 2773–2778, 2012. View at: Google Scholar
  22. B. Foxman, “The epidemiology of vulvovaginal candidiasis: risk factors,” American Journal of Public Health, vol. 80, no. 3, pp. 329–331, 1990. View at: Publisher Site | Google Scholar
  23. M. J. Richards, J. R. Edwards, D. H. Culver, and R. P. Gaynes, “Nosocomial infections in combined medical-surgical intensive care units in the United States,” Infection Control and Hospital Epidemiology, vol. 21, no. 8, pp. 510–515, 2000. View at: Publisher Site | Google Scholar
  24. N. Paul, E. Mathai, O. C. Abraham, J. S. Michael, and D. Mathai, “Factors associated with candiduria and related mortality,” Journal of Infection, vol. 55, no. 5, pp. 450–455, 2007. View at: Publisher Site | Google Scholar
  25. S. Natalie, “Recurrent vulvovaginal candidiasis,” South African Pharmaceutical Journal, vol. 79, no. 6, pp. 14–17, 2012. View at: Google Scholar
  26. T. E. Brown, L. D. Dresser, and T. W. F. Chin, “Superficial fungal infections,” in Pharmacotherapy: A Pathophysiologic Approach, J. T. DiPiro, R. L. Talbert, and G. C. Yee, Eds., The McGraw-Hill Companies, New York, NY, USA, 8th edition, 2011. View at: Google Scholar
  27. M. Cheesbrough, District Laboratory Practice in Tropical Countries—Part 2, Cambridge University Press, Cambridge, UK, 2000.
  28. H. W. Boucher, A. H. Groll, C. C. Chiou, and T. J. Walsh, “Newer systemic antifungal agents: pharmacokinetics, safety and efficacy,” Drugs, vol. 64, no. 18, pp. 1997–2020, 2004. View at: Publisher Site | Google Scholar
  29. M. A. Pfaller and D. J. Diekema, “Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus,” Journal of Clinical Microbiology, vol. 42, no. 10, pp. 4419–4431, 2004. View at: Publisher Site | Google Scholar
  30. E. van Dyck, A. Z. Mehem, and P. Piot, Laboratory Diagnosis of Sexually Transmitted Diseases, World Health Organization, Geneva, Switzerland, 1999.
  31. I. B. Enweani, C. I. C. Ogbonna, and W. Kozak, “The incidence of candidiasis amongst the asymptomatic female students of the University of Jos, Nigeria,” Mycopathologia, vol. 99, no. 3, pp. 135–141, 1987. View at: Publisher Site | Google Scholar
  32. S. C. Sehgal, “Epidemiology of male urethritis in Nigeria,” Journal of Tropical Medicine and Hygiene, vol. 93, no. 2, pp. 151–152, 1990. View at: Google Scholar
  33. F. I. Okungbowa, O. S. Isikhuemhen, and A. P. O. Dede, “The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities,” Revista Iberoamericana de Micologia, vol. 20, no. 2, pp. 60–63, 2003. View at: Google Scholar
  34. J. Farooqi, K. Jabeen, N. Saeed, A. Zafar, M. E. Brandt, and R. Hasan, “Species identification of invasive yeasts including Candida in Pakistan: limitations of phenotypic methods,” Journal of the Pakistan Medical Association, vol. 62, no. 10, pp. 995–998, 2012. View at: Google Scholar
  35. M. Srujana, I. Xess, F. Hassan, A. Kapil, S. Mittal, and J. E. Tolosa, “Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis,” The Indian Journal of Medical Research, vol. 126, no. 3, pp. 216–219, 2007. View at: Google Scholar
  36. V. D. Malini, “Characterization and antifungal susceptibility of Candida species: a preliminary study,” Journal of Academic and Clinical Microbiology, vol. 2, no. 15, pp. 55–57, 2000. View at: Google Scholar
  37. A. K. Ragini, B. Sandhya, D. Gayatri, and Indumati, “Characterization and antifungal susceptibility testing for Candida species in a tertiary care hospital,” Journal of Health Sciences and Research, vol. 2, no. 2, pp. 1–7, 2011. View at: Google Scholar
  38. D. Taura, M. Maje, A. Koki, and M. Musa, “Antifungal resistance among Candida species from patients with genitourinary tract infection at Muhammad Abdullahi Wase Specialist Hospital, Kano,” Nigerian Journal of Basic and Applied Sciences, vol. 21, no. 1, pp. 33–38, 2013. View at: Publisher Site | Google Scholar
  39. G. Ginter, H. P. Soyer, and E. Rieger, “Vaginal yeast colonization and promiscuity. A study of 197 prostitutes,” Mycoses, vol. 35, no. 7-8, pp. 177–180, 1992. View at: Google Scholar
  40. A. K. Ako-Nai, O. O. Kassim, M. O. Adeniran, and O. Taiwo, “A study of urinary tract infections at Ile-Ife, Nigeria,” East African Medical Journal, vol. 70, no. 1, pp. 10–14, 1993. View at: Google Scholar
  41. J. M. Baeten, P. M. Nyange, B. A. Richardson et al., “Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study,” American Journal of Obstetrics & Gynecology, vol. 185, no. 2, pp. 380–385, 2001. View at: Publisher Site | Google Scholar
  42. I. B. Enweani, H. C. Gugnani, R. Okobia, and S. B. Ojo, “Effect of contraceptives on the prevalence of vaginal colonization with Candida species in Edo State, Nigeria,” Revista Iberoamericana de Micologia, vol. 18, no. 4, pp. 171–173, 2001. View at: Google Scholar
  43. M. A. Yusuff, A. Q. Chowdhury, A. N. I. Sattar, and M. Rahman, “Evaluation of the effect of contraceptives on prevalence of Candida species on vaginal candidiasis in Dhaka, Bangladesh,” Bangladesh Journal of Medical Microbiology, vol. 1, no. 2, pp. 61–64, 2007. View at: Google Scholar
  44. S. S. Taiwo, A. B. Ashubiaro, A. I. Olugbenga-Bello, D. P. Oparinde, E. O. Asekun-Olarinmoye, and J. O. Ashiru, “Pattern of sexually transmitted diseases seen at Ladoke Akintola University Teaching Hospital, Osogbo, Southwestern Nigeria,” Nigerian Journal of Genitourinary Medicine, vol. 3, no. 1-2, pp. 4–7, 2004. View at: Google Scholar
  45. H. C. Gugnani, F. K. Nzelibe, P. C. Gini, W. O. Chukudebelu, and A. N. U. Njoku-Obi, “Incidence of yeasts in pregnant and non-pregnant women in Nigeria,” Mycoses, vol. 32, no. 3, pp. 131–135, 1989. View at: Google Scholar
  46. M. M. Barousse, B. J. Van Der Pol, D. Fortenberry, D. Orr, and P. L. Fidel Jr., “Vaginal yeast colonisation, prevalence of vaginitis, and associated local immunity in adolescents,” Sexually Transmitted Infections, vol. 80, no. 1, pp. 48–53, 2004. View at: Publisher Site | Google Scholar

Copyright © 2015 Oluranti J. Obisesan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.